MRSA and complicated skin and soft tissue infections

MRSA

Volumn , Issue , 2007, Pages 55-70

  Itani, Kamal M F ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79551563743     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (31)

1. Uncomplicated and complicated skin and skin structure infections— developing Antimicrobial drugs for treatment: Guidance for Industry. www.fda.gov/cder/guidance/2566dfr.pdf7-22-1998. Last accessed August 12, 2006.
2. Rennie RP, Jones RN, Mutnick AH; SENTRY Program Study Group (North America). Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000). Diagn Microbiol Infect Dis 2003; 45(4):287-293.
3. Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. J Am Med Assoc 2003; 290(22):2976-2984.
4. Weber JT. Community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2005; 41(suppl 4):S269-S272.
5. Baggett HC, Hennessy TW, Rudolph K, et al. Community-onset methicillin-resistant Staphylococcus aureus associated with antibiotic use and the cyto-toxin Panton-Valentine leukocidin during a furunculosis outbreak in rural Alaska. J Infect Dis 2004; 189(9):1565-1573.
6. Miller LG, Perdreau-Remmington F, Rieg G, et al. Necrotizing fascitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005; 352:1445-1453.
7. Horan TC, Gaynes RP, Martone WJ, et al. CDC definitions of nosocomial surgical site infections. Infect Control Hosp Epidemiol 1992; 13:606-608.
8. Culver DH, Horan TC, Gaynes RP, et al. Surgical wound infection rates by wound class, operative procedure, and patient risk index. Am J Med 1991; 91 (suppl 3B):152-157.
9. Knight R, Charbonneau P, Ratzer E, et al. Prophylactic antibiotics are not indicated in clean general surgery cases. Am J Surg 2001; 182:682-686.
10. Rennie RP, Jones RN, Mutnick AH; SENTRY Study Group (North America). Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infection: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000). Diagn Microbial Infect Dis 2003; 45:287-293.
11. Doern GV, Jones RN, Pfaller MA, et al. and the SENTRY study group (North America). Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). Diagn Microbiol Infect Dis 1999; 34:65-72.
12. Kaye KS, Engemann JJ, Mozaffari E, Carmeli Y. Reference group choice and antibiotic resistance outcomes. Emerg Infect Dis 2004; 10(6):1125-1128.
13. Engemann JJ, Carmeli Y, Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003; 36(5):592-598.
14. Bratzler DW, Houck PM; Surgical Infection Prevention Guidelines Writers Workgroup. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis2004; 38(12):1706.
15. Perl TM, Cullen JJ, Wenzel RP, Zimmerman MB, et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infection. N Engl J Med 2002Jun 13; 346(24):1871-1877.
16. Rao N, Jacobs S, Joyce L. Cost-effective eradication of an outbreak of methicillin-resistant Staphylococcus aureus in a community teaching hospital. Infect Control Hosp Epidemiol 1988 Jun; 9(6):255-260.
17. Huh SY, Daya M. Dermatology Quiz. Resident and staff physician 2006; 852(6):37-38.
18. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis, WR. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infec Control Hosp Epidemiol 1999; 20(4):250-278.
19. Lipsky BA, Berendt AR, Deery HG, et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2004; 39(7):885-910.
20. Stevens DL. The relevance of antibiotic tissue penetration for treating complicated skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus: an evidence-based review. Med Ed Direct 2004; 4:1-6.
21. Rezende NA, Blumberg HM, Metzger BS, Larsen NM, Ray SM, Mc Gowan JE Jr. Risk factors for methicillin resistance among patients with Staphylococcus aureus bacteremia at the time of hospital admission. Am J Med Sci 2002; 323:117-123
22. Lodise TP Jr, McKinnon PS, Rybak M. Prediction model to identify patients with Staphylococcus aureus bacteremia at risk of methicillin resistance. Infect Control Hosp Epidemiol 2003; 24:655-661.
23. Siberry GK, Tekle T, Carroll K, Dick J. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 2003; 37:1257-1260.
24. Schrenzel J, Harbarth S, Schockmel G, et al. Swiss Staphylococcal Study Group. A randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection. Clin Infect Dis 2004; 39:1285-1292.
25. Itani KMF. Infections in the surgical patient: an update on trends and treatments. Am J Surg 2003; 186(5A):1S-3S.
26. Weigelt JA, Itani KMF, Stevens D, Lau WK, Dryden M, Knirsch C. Linezolid vs vancomycin in the treatment of complicated skin and soft tissue infections. Antimicrob Agents Ch 2005; 49(6):1-7.
27. Weigelt J, Kaafarani HMA, Itani KMF, Swanson RN. Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am J Surg2004; 188:760-766.
28. Itani KMF, Weigelt J, Li JZ, Duttagupta S. Linezolid reduces length of stay and intravenous therapy duration compared with vancomycin for complicated skin and soft tissue infections due to suspected methicillin resistant Staphylococcus aureus.Int J Antimicrob Agents 2005; 26(6):442-448.
29. Mc Kinnon PS, Sorensen S, Liu L, Itani KMF. The impact of linezolid on economic outcomes and determinants of cost in patients with documented or suspected MRSA complicated skin and soft-tissue infections. Annals of Pharmacotherapy 2006; 40(6):1017-1023.
30. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI; Daptomycin 98-01 and 99-01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38:1673-1681.
31. Breedt J, Teras J, Gardovskis J, et al.; Tigecycline 305 cSSSI Study Group. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005; 49(11):4658-4666.